The concentration of TRAIL used to kill CLL (500 ng/ml) cells was comprised between the residual and the maximum of the TRAIL concentration measured in the sera of patients included in phase Ia and Ib clinical trials [31]. This evidence concerns the gene TNFSF10 and B-cell chronic lymphocytic leukemia.